World Malaria Day 2019

Novartis reaffirms commitment to fighting malaria and recognizes the dedication of our people and partners.
Apr 25, 2019

Novartis has been committed to the fight against malaria for the past two decades. In 1999 we launched the first fixed-dose Artemisinin-based combination therapy (ACT) and in 2009 the first dispersible pediatric ACT developed in partnership with Medicines for Malaria Venture (MMV). Today we are working on the development of the next generation of antimalarials.

Over the past 20 years, together with our partners, we have delivered more than 880 million treatments, including over 370 million pediatric treatments, without profit to malaria-endemic countries.

Follow us on social media at #MalariaFuture

Working toward a malaria-free world

Despite the tremendous progress made in combating malaria, one child still dies from the disease every two minutes. Novartis is commited to contribute to the WHO's target of reducing malaria-related child mortality by at least 90% in 2030.

Working on the next generation of antimalarials

"Resistance to treatment presents the biggest threat to the incredible progress that has been made in the fight against malaria in the past 20 years. We cannot afford to wait; this is why we are committing to advance the research and development of next-generation treatments," said Vas Narasimhan, CEO of Novartis.

Nurse using microscope to diagnose malaria in Kenya.

Europe-Africa partnership spearheads development of next-generation antimalarial drug.

Read the press release

Local insights and learnings are key to accelerating progress

Novartis launches its second opinion research study, Malaria Futures for Asia (MalaFAsia), capturing the views of Asian malaria experts – from government, the research community and NGOs – on progress and challenges toward the 2030 global malaria goals.

Malaria Futures for Asia – MalaFAsia report.

Read the story

Read the press release

Read the full report

Read more about the earlier Malaria Futures for Africa study

How can digital help to fight malaria?

Bertrand Bodson, Chief Digital Officer at Novartis, shares his experience when he had malaria as a child. He highlights how digital can help to fight and eliminate malaria.

Novartis Social Business (NSB)

NSB supports global public health through novel sustainable business models. Our activities are rooted in local communities, where we work with partners to provide affordable, high-quality medicines against infectious and chronic diseases while strengthening healthcare capacity. Everything we do relies on our network of partners, who share our purpose.

Learn More

Novartis Social Business on social media: LinkedIn Twitter